Splenic marginal zone lymphomas (SMZLs) are rare indolent B cell neoplasms that affect the spleen, bone marrow, and blood. Although they have an indolent course in the majority of patients, who have a median survival of 8-10 years, ∼ 30% may experience a worse outcome. The prognostic criteria of progression are lymph node and extra-nodal involvement, high lymphocyte counts, anaemia, and thrombocytopenia. The treatment of SMZLs include a "wait and watch strategy", splenectomy, and alkylating agents ± rituximab. We here describe data relating to 70 patients with intermediate-/high-risk SMZLs, who received rituximab/bendamustine as first-line treatment for a median of 60 days (range 1-75) after diagnosis. Sixty patients (86%) achieved a complete response (CR), and seven (10%) a partial response (PR). Three patients (4.3%) experienced disease progression (PD). The median duration of remission was 18 months. Side effects were generally mild. Our findings suggest that rituximab/bendamustine is a feasible treatment option in patients with intermediate-/high-risk SMZLs.
First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas / R. Castelli, L.C. Bergamaschini, G.L. Deliliers. - In: MEDICAL ONCOLOGY. - ISSN 1357-0560. - 35:2(2018 Feb), pp. 15.1-15.7.
|Titolo:||First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas|
CASTELLI, ROBERTO [Writing – Review & Editing] (Corresponding)
BERGAMASCHINI, LUIGI CESARE [Writing – Original Draft Preparation]
LAMBERTENGHI DELILIERS, GIORGIO [Supervision]
|Parole Chiave:||Bendamustine; Indolent lymphoproliferative disease; Intermediate-/high-risk patients; Rituximab; Splenic marginal zone lymphoma (SMZL); Hematology; Oncology; Cancer Research|
|Settore Scientifico Disciplinare:||Settore MED/09 - Medicina Interna|
|Data di pubblicazione:||feb-2018|
|Data ahead of print / Data di stampa:||29-dic-2017|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1007/s12032-017-1076-1|
|Appare nelle tipologie:||01 - Articolo su periodico|